Spectrum Pharmaceuticals Aktie [WKN: 164623 / ISIN: US84763A1088]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Spectrum Pharmaceuticals IncShs

03.08.20		Spectrum Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Corporate Update (Businesswire)
30.07.20		Spectrum Pharmaceuticals Announces Pricing of Public Offering of Common Stock (Businesswire)
30.07.20		Pre-market Movers In Healthcare Sector: CLRB, ADMA, AMAG, BNGO, SNOA... (RTTNews)
29.07.20		Spectrum Pharmaceuticals Announces Proposed Public Offering of Common Stock (Businesswire)
28.07.20		Stock Alert: Spectrum Pharma Shares Up 29% (RTTNews)
28.07.20		Pre-market Movers In Healthcare Sector: SPPI, MEDS, OCGN, SRNE, CRMD... (RTTNews)
28.07.20		MRNA, PFE/BNTX COVID-19 Vaccines Move Into Phase 3, CytoDyn On Watch, GNCA To Report Data On Jul.30 (RTTNews)
27.07.20		Spectrum Pharmaceuticals Announces Positive Topline Results in HER2 Exon20 Insertion Mutations from Cohort 2 of the Poziotinib ZENITH20 Trial (Businesswire)
22.06.20		Spectrum Pharmaceuticals Presents Same Day Dosing Data for ROLONTIS® (eflapegrastim) at AACR Virtual Annual Meeting II (Businesswire)
16.06.20		Spectrum Pharmaceuticals to Present Preclinical ROLONTIS® (eflapegrastim) Same Day Dosing Data at AACR Virtual Annual Meeting II (Businesswire)
03.06.20		Spectrum Pharmaceuticals Appoints Lyndah K. Dreiling, M.D., MBA, as Senior Vice President, Clinical Development (Businesswire)
07.05.20		Spectrum Pharmaceuticals Reports First Quarter 2020 Financial Results and Pipeline Update (Businesswire)
01.05.20		Spectrum Pharmaceuticals to Report First Quarter 2020 Financial Results and Provide Corporate Update (Businesswire)
30.04.20		Spectrum Pharmaceuticals Initiates Same Day Dosing Clinical Trial for ROLONTIS® (eflapegrastim) (Businesswire)
28.04.20		Spectrum Pharmaceuticals Provides Strategy Update for Poziotinib Development Program (Businesswire)
23.04.20		Spectrum Pharmaceuticals Appoints Seth H.Z. Fischer to Board of Directors (Businesswire)
21.04.20		Spectrum Pharmaceuticals to Present Data from Phase 2 Clinical Trial for Poziotinib at American Association for Cancer Research Virtual Annual Meeting 2020 (Businesswire)
17.03.20		Spectrum Pharmaceuticals Cancelled Participation in Upcoming Medical Conference Due to Coronavirus Pandemic (Businesswire)
11.03.20		Spectrum Pharmaceuticals to Present Data from Phase 2 Clinical Trial for Poziotinib at Upcoming Medical Conference (Businesswire)
03.03.20		Spectrum Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2020 (Businesswire)
27.02.20		Spectrum Pharmaceuticals Reports Fourth Quarter 2019 and Full Year 2019 Financial Results and Pipeline Update (Businesswire)
20.02.20		Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results Conference Call (Businesswire)
06.02.20		Spectrum Pharmaceuticals to Present Corporate Update at the Guggenheim Healthcare Talks Idea Forum Oncology Day on February 13th (Businesswire)
26.12.19		Spectrum Pharma's Lung Cancer Treatment Trial Misses Main Goal; Stock Drops (RTTNews)
26.12.19		Spectrum Pharmaceuticals Provides Pipeline Update on Late Stage Programs (Businesswire)
14.11.19		Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2019 London Healthcare Conference on November 21st (Businesswire)
07.11.19		Spectrum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Pipeline Update (Businesswire)
31.10.19		Spectrum Pharmaceuticals Announces Third Quarter 2019 Financial Results Conference Call (Businesswire)
24.10.19		Spectrum Pharmaceuticals Announces Submission to the U.S. Food and Drug Administration of Updated Biologics License Application for ROLONTIS® (Businesswire)
04.10.19		Spectrum Pharmaceuticals Announces Publication of Positive Poziotinib Data in Cancer Cell (Businesswire)
25.09.19		Spectrum Pharmaceuticals to Present Corporate Update at the 2019 Cantor Global Healthcare Conference on October 2nd (Businesswire)
06.09.19		Spectrum Announces Poziotinib Data Being Presented at the IASLC 2019 World Conference on Lung Cancer (Businesswire)
03.09.19		Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September (Businesswire)
08.08.19		Spectrum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Pipeline Update (Businesswire)
01.08.19		Spectrum Pharmaceuticals Announces Second Quarter 2019 Financial Results Conference Call (Businesswire)
22.07.19		Spectrum Announces Expansion of the Poziotinib Clinical Program (Businesswire)
20.06.19		Spectrum Pharmaceuticals Appoints Elizabeth Czerepak to its Board of Directors (Businesswire)
02.06.19		Spectrum Pharmaceuticals Announces Integrated Results from Two Phase 3 ROLONTIS® (eflapegrastim) Trials Being Presented at the ASCO Annual Meeting (Businesswire)
29.05.19		Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2019 Global Healthcare Conference on June 5th (Businesswire)
28.05.19		Spectrum Announces Poziotinib ZENITH20 Trial HER2 Cohort (Cohort 2) Has Reached Enrollment Target (Businesswire)
16.05.19		Spectrum Pharmaceuticals to Present Corporate Update at the 20th Annual B. Riley FBR Investor Conference on May 23rd (Businesswire)
09.05.19		Spectrum Pharmaceuticals Reports First Quarter 2019 Financial Results and Pipeline Update (Businesswire)
09.05.19		Spectrum Announces Asset Purchase and License for a Novel Immuno-Oncology Platform including Two Early Stage Assets (Businesswire)
02.05.19		Spectrum Pharmaceuticals Announces First Quarter 2019 Financial Results Conference Call (Businesswire)
02.04.19		Spectrum Pharmaceuticals to Present Corporate Update at the H.C. Wainwright Global Life Sciences Conference on April 9 (Businesswire)
15.03.19		Spectrum Pharmaceuticals Provides BLA Filing Update for ROLONTIS® (eflapegrastim) (Businesswire)
13.03.19		Spectrum Pharmaceuticals to Present Corporate Update at the Oppenheimer 29th Annual Healthcare Conference on March 20 (Businesswire)
01.03.19		Spectrum Pharmaceuticals Announces the Completion of the Sale of its Marketed Portfolio (Businesswire)
28.02.19		Spectrum Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results and Pipeline Update (Businesswire)
21.02.19		Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results Conference Call (Businesswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

NVIDIA vor Q3-Ergebnissen: Hohe Erwartungen und höhere Kursziele für den KI-Giganten

Solana noch in diesem Jahr bei 300 US-Dollar?

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

BlackRocks Bitcoin-ETF überholt Gold-ETF

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	22.11.2024 22:24
Kaufwert:	EUR
	Hinzufügen Speichern